Company intelligence / Profile preview

Mabylon AG

Schlieren, Zurich, Switzerlandmabylon.com ↗

Ownership: Private
Development stage: Other

Overview

Mabylon AG develops fully human monoclonal antibodies using advanced B-cell screening technologies. Its lead program, MY006—a multi-specific antibody therapeutic targeting peanut allergy—has shown promising preclinical results in preventing anaphylaxis in animal models. The company has entered into a partnership with Pfizer Ignite to accelerate the development of its anti-peanut allergy candidate. Other pipeline programs target severe allergies, inflammatory conditions, and neurological disorders.

Therapeutic areas: ImmunologyNeurology
Modalities: monoclonal antibodies (mAbs)human-derived antibodies
Industry: Biotech

Drug pipeline

5 assets

MY006

4 more assets in the full pipeline.

Request access →

Partnerships

Pfizer Ignite (for expedited development of anti-peanut-allergy therapeutic)

Beyond the preview

Go deeper on Mabylon AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mabylon AG.

Explore the full profile